What is MOTS-c and why does source documentation matter for research buyers?
MOTS-c (mitochondrial open-reading-frame of the twelve S rRNA type-c) is a short peptide encoded within the mitochondrial 12S rRNA region and first described as a mitochondrial-derived peptide in 2015 (PMID:25738459). Subsequent work has characterised it as a regulator implicated in metabolic stress signalling, with reports that it can translocate to the nucleus under metabolic stress (PMID:29983246) and reviews cataloguing its molecular biology (PMID:36761202; PMID:36670507). For a research buyer in Australia, none of that biology is useful unless the material in the vial actually corresponds to the published sequence at a defined purity. That is where documentation becomes decisive. A certificate of analysis translates an anonymous white powder into a characterised reagent: it should state the claimed sequence, the measured molecular mass, the chromatographic purity, the net peptide content and the counterion identity. Because MOTS-c is a small, relatively hydrophilic peptide, common failure modes include truncated sequences from incomplete synthesis, deamidation of susceptible residues, and residual trifluoroacetate from purification. Each of these is detectable analytically, and each should be addressed — explicitly or by omission you can question — in the paperwork. When you compare Australian suppliers, treat the CoA as the primary product, and the peptide as its physical instantiation. A supplier that cannot produce a lot-specific CoA, only a generic template, is asking you to accept identity and purity on faith. The checklist that follows lets you replace faith with verification, and it applies equally whether you are buying a single research vial or a multi-vial lot.
How do you verify MOTS-c identity on a certificate of analysis?
Identity verification answers a single question: is this molecule the MOTS-c sequence it claims to be? The primary tool is mass spectrometry. A credible CoA reports an observed molecular mass from electrospray ionisation (ESI-MS) or MALDI-TOF and compares it to the theoretical monoisotopic or average mass calculated from the stated sequence. For a 16-residue peptide, the observed and theoretical masses should agree closely; a large discrepancy signals a wrong sequence, a modification, or a mislabelled vial. Ask whether the report shows the actual deconvoluted spectrum or merely a numeric value — a spectrum lets you confirm there is a single dominant species rather than a mixture. For higher assurance, sequence-level confirmation via tandem mass spectrometry (MS/MS) maps fragment ions back to the amino-acid sequence, distinguishing MOTS-c from a same-mass impurity or a scrambled sequence. Where a supplier offers orthogonal confirmation — for example an independent method or a second laboratory checking identity — that materially strengthens the record. Cross-reference the sequence printed on the CoA against the published MOTS-c sequence in the primary literature (PMID:25738459) so that you are validating against the source, not against the vendor's own restatement. Finally, confirm the CoA carries a lot or batch number that also appears on the vial label and, ideally, in an order-linked traceability record. Identity documentation without a traceable lot number is unverifiable in practice: you cannot prove the spectrum on the page came from the powder in your freezer. A robust identity package therefore combines a mass measurement, ideally a spectrum, sequence confirmation where available, and an unbroken lot linkage from paperwork to physical unit.
What purity and impurity data should a MOTS-c batch report include?
Purity on a peptide CoA is almost always a chromatographic purity, most commonly by reversed-phase HPLC with UV detection, expressed as the percentage of total peak area attributable to the main peak. Read this figure critically. First, check the reported wavelength and the integration parameters: a purity value is only meaningful alongside the peak-threshold and area-percent conventions used to generate it. Second, look for a peak-purity assessment using diode-array detection (HPLC-DAD), which tests whether the main peak is spectrally homogeneous or hides a co-eluting impurity — a peak that looks single by area can still be impure. Third, a strong report characterises the named related substances rather than lumping everything into 'other'. For a synthetic peptide like MOTS-c, expected impurities include truncation and deletion sequences, and oxidation or deamidation products; LC-MS impurity profiling can assign masses to these minor peaks so you know what the balance of the sample is, not just how much of it is not the target. Where the CoA gives a single purity number with no method detail, treat it as a headline figure requiring corroboration. Acceptance criteria matter too: a specification should state the minimum purity the lot was released against, so you can judge whether the measured value comfortably clears the limit or barely scrapes it. Orthogonal purity checks — for instance combining an area-percent HPLC result with an LC-MS mass-balance reconciliation — reduce the risk that a single method masks a problem. When comparing Australian suppliers, prefer batch reports that disclose the method, wavelength, acceptance limit, and any characterised impurities, rather than an isolated percentage that cannot be independently interrogated.
How is MOTS-c quantified, and why do net peptide content and counterion matter?
A vial labelled with a nominal peptide mass rarely contains that mass of pure peptide. Lyophilised synthetic peptides are salts, and they retain bound water and residual counterions, so the gross powder weight overstates the actual peptide present. Net peptide content — the fraction of the powder that is genuinely peptide — is therefore a critical quantification field. It is typically derived from amino-acid analysis or from UV/quantitative approaches, and it should be reported as a percentage or as an absolute peptide mass per vial. Without it, any concentration a researcher calculates from label mass will be systematically wrong, undermining reproducibility across experiments and between lots. Closely related is counterion identity and content. Peptides purified by reversed-phase HPLC commonly carry trifluoroacetate (TFA); some are exchanged to acetate. TFA is spectroscopically and biologically relevant in cell-based research, so a CoA that quantifies the counterion (for example by ion chromatography) tells you both what salt form you have and how much of the powder mass it accounts for. Water content, often measured by Karl Fischer titration, closes the mass balance: peptide plus counterion plus water plus any residual solvent should broadly reconcile with 100 per cent. When these fields are present, you can convert a stated purity and net content into a defensible working concentration and compare lots on a like-for-like basis. When they are absent, you are guessing. In practical terms, a purchase-ready MOTS-c CoA should let you answer: how much peptide is actually here, in what salt form, and how much of the weight is water — because those three numbers, not the label, define what you are buying.
What stability and storage documentation strengthens a MOTS-c purchase decision?
Stability documentation tells you whether the analytical picture on the CoA will still hold by the time material reaches your bench and through your intended study window. Peptides degrade by defined chemical routes — oxidation of susceptible residues, deamidation, aggregation and hydrolysis — and a supplier that understands these pathways can describe how the lyophilised material should be handled and reconstituted to preserve it. Look for guidance on the recommended storage state of the dry powder, on appropriate reconstitution solvents, and on the expected behaviour of the reconstituted solution, ideally supported by the supplier's own forced-degradation or stability study design rather than generic claims. Freeze-thaw considerations are relevant because repeated cycling of a reconstituted stock can promote degradation and adsorptive losses; a report that acknowledges this, and that discusses peptide adsorption to glass and plastic surfaces, reflects genuine analytical competence. For local Australian purchasing, the logistics angle is about the paper trail rather than any temperature-controlled transport: prefer suppliers holding local stock with tracked dispatch and per-lot documentation, so the interval between characterisation and delivery is short and fully documented. This lets you tie the CoA analysis date to the dispatch date and assess how current the data are. A useful supplementary question is whether the supplier retains a reference standard or retention sample of the lot, which supports later re-testing if you ever need to confirm identity or purity again. None of this concerns any use of the peptide; it concerns whether the characterised material you paid for is the material you receive, and whether it can be stored and reconstituted without silently drifting away from its CoA.
How do you evaluate an Australian MOTS-c supplier beyond the product page?
Once the CoA fields are satisfied, evaluate the supplier as a documentation system, not a single listing. First, lot traceability: can the supplier link a specific vial, by batch number, to a specific analytical report, and does that number appear consistently on the label, the CoA and any order paperwork? A broken chain here defeats every other check. Second, per-lot rather than per-product documentation: reputable batch testing generates fresh data for each production lot, so ask whether the CoA you are shown corresponds to the lot you will actually receive, not an archived exemplar. Third, method transparency: a supplier confident in its analysis will name the techniques — HPLC purity, ESI or MALDI-TOF mass confirmation, amino-acid analysis, Karl Fischer, counterion analysis — and state acceptance criteria, rather than presenting bare numbers. Fourth, consistency across a multi-vial or bulk order: if you buy several vials of one lot, they should share a single batch report, and the documentation should make per-vial traceability explicit. Fifth, research-only framing: a compliant Australian vendor presents material strictly for laboratory research, without human-use guidance, which is itself a signal of a serious operation. Reviews and reputation queries (for example searches asking whether a vendor is genuine) are a weak proxy; documentation you can independently interrogate is a strong one. Treat the whole evaluation as evidence-gathering: request a sample CoA before ordering, verify the sequence against the primary MOTS-c literature (PMID:25738459; PMID:36761202), check that identity, purity, quantification and stability fields are all populated, and confirm the batch number traceability. A supplier that welcomes this scrutiny — and supplies the underlying method detail — is the one worth buying from.
Order Mots C with documentation
If this guide helped you evaluate Mots C for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Mots C card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is MOTS-c legal to buy in Australia?
MOTS-c can be supplied within Australia as a research reagent for laboratory use only. It is not offered or discussed here for any human application. Buyers should confirm their purchase is for legitimate research purposes and evaluate the supplier's documentation, compliance framing and lot traceability before ordering.
How do I confirm MOTS-c identity before I buy?
Check the certificate of analysis for a mass-spectrometry result (ESI-MS or MALDI-TOF) that matches the theoretical mass of the stated 16-residue sequence, ideally shown as a spectrum. Cross-reference the sequence against the published MOTS-c literature, and confirm the lot number on the CoA matches the vial label.
What purity should a MOTS-c certificate of analysis report?
Look for a chromatographic purity by reversed-phase HPLC with the wavelength and integration settings disclosed, a stated acceptance limit, and ideally a diode-array peak-purity check plus LC-MS characterisation of named impurities such as truncation or oxidation products. A bare percentage without method detail warrants further questions.
Why does net peptide content matter when buying MOTS-c?
A lyophilised peptide vial contains peptide plus counterion and water, so the powder weight overstates actual peptide. Net peptide content, typically from amino-acid analysis, tells you how much peptide is truly present, which is essential for accurate, reproducible concentration calculations across lots and experiments.
Does buying MOTS-c locally in Australia offer any advantage?
Local Australian stock with tracked dispatch shortens the documented interval between analysis and delivery and makes per-lot paperwork easier to request up front. This is a logistics and documentation advantage only; it says nothing about how any material may be used.
References
- PMID:25738459 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metab — 2015
- PMID:29983246 — The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Cell Metab — 2018
- PMID:36761202 — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne) — 2023
- PMID:36670507 — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging — J Transl Med — 2023
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
